Fairvalue-Calculator Fairvalue-Calculator
EN DE

GlycoNex Incorporation (4168) Fair Value & Analysis

Healthcare · TW · Market cap 3.0B TWD

Price25.00 TWD
Fair Value39.29 TWD
Upside+57.2%
Quality95/100
Evidence: Low Range 29.46 TWD – 49.11 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

GlycoNex Incorporation (4168) currently trades at 25.00 TWD, while our model-based Fair Value estimate is 39.29 TWD — implying the stock looks roughly 57.2% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Japan and Taiwan. The company's pipeline under the BLA stage consists of SPD8-P, a Prolia biosimilar for the treatment of osteoporosis; and SPD8-R, a Xgeva biosimilar for the treatment of bone cancer metastases. It also develops GNX102, a humanized monoclonal antibody, which is in Phase 1 clinical trials for the treatment of various solid tumor types, such as colorectal, gastric, lung, breast, and pancreatic cancers; GNX1021, an antibody"drug conjugate that has completed the preclinical stage for oncology indications; GNX201-ADC, an antibody drug in the preclinical stage for the treatment of solid tumors; and GNX203, a glycan-directed antibody drug currently in the lead optimization stage for the treatment of solid tumors, including pancreatic, colorectal, and gynecologic cancers. In addition, the company offers technical consulting services…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is GlycoNex Incorporation (4168) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 39.29 TWD versus a price of 25.00 TWD — about +57% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 4168?
Our 21-model fair value for GlycoNex Incorporation is 39.29 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 25.00 TWD.
What is the quality score of 4168?
GlycoNex Incorporation has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.